Spine BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease byJosh SandbergFebruary 5, 2024
Biologics Spine BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting byJosh SandbergFebruary 1, 2024
Biologics Spine BioRestorative Therapies Announces Activation of Northwell Health in the Company’s Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease byJosh SandbergSeptember 8, 2023
Biologics BioRestorative Therapies Announces $2.1 Million Registered Direct Offering byJosh SandbergJuly 11, 2023
Biologics BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease byJosh SandbergJune 12, 2023
Biologics BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing byJosh SandbergMay 31, 2023
Biologics Spine BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease byChris StewartDecember 5, 2022
Biologics Spine BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byChris StewartJune 30, 2022
Biologics Spine BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byChris StewartJune 22, 2022
Biologics Spine BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) byJosh SandbergJune 13, 2022
